Literature DB >> 11980661

Semaphorin 3F gene from human 3p21.3 suppresses tumor formation in nude mice.

RuiHua Xiang1, Albert R Davalos, Charles H Hensel, Xiao-Jun Zhou, Christin Tse, Susan L Naylor.   

Abstract

Loss of heterozygosity on human chromosome 3p21.3 is a frequent occurrence in many tumor types. In a previous study, our laboratory demonstrated that an 80-kb P1 clone from chromosome 3 suppresses the tumorigenicity of the mouse fibrosarcoma cell line A9. Two cDNAs corresponding to genes encoded on this P1 clone, semaphorin 3F (SEMA3F) and N23, were tested for their effects on in vitro and in vivo growth characteristics after transfection into mouse A9 cells. Transfection of SEMA3F cDNA resulted in complete loss of tumorigenicity in nude mice, whereas transfection of N23 had no effect. Moreover, SEMA3F also functioned to block apoptosis of transfected A9 cells treated with Taxol or Adriamycin. The human ovarian adenocarcinoma cell line HEY showed a similar result as A9 cells, but the small cell lung cancer line GLC45 was unaffected by expression of SEMA3F.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11980661

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  45 in total

Review 1.  To move or not to move? Semaphorin signalling in cell migration.

Authors:  Luca Tamagnone; Paolo M Comoglio
Journal:  EMBO Rep       Date:  2004-04       Impact factor: 8.807

Review 2.  Semaphorins in angiogenesis and tumor progression.

Authors:  Gera Neufeld; Adi D Sabag; Noa Rabinovicz; Ofra Kessler
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

3.  Semaphorin 4D provides a link between axon guidance processes and tumor-induced angiogenesis.

Authors:  John R Basile; Rogerio M Castilho; Vanessa P Williams; J Silvio Gutkind
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-05       Impact factor: 11.205

4.  Selective suppression of in vivo tumorigenicity by semaphorin SEMA3F in lung cancer cells.

Authors:  Sophie Kusy; Patrick Nasarre; Daniel Chan; Vincent Potiron; David Meyronet; Robert M Gemmill; Bruno Constantin; Harry A Drabkin; Joëlle Roche
Journal:  Neoplasia       Date:  2005-05       Impact factor: 5.715

Review 5.  Signal transduction in vasculogenesis and developmental angiogenesis.

Authors:  Sunita Patel-Hett; Patricia A D'Amore
Journal:  Int J Dev Biol       Date:  2011       Impact factor: 2.203

6.  Semaphorin-3D and semaphorin-3E inhibit the development of tumors from glioblastoma cells implanted in the cortex of the brain.

Authors:  Adi D Sabag; Julia Bode; Dorit Fink; Boaz Kigel; Wilfried Kugler; Gera Neufeld
Journal:  PLoS One       Date:  2012-08-24       Impact factor: 3.240

Review 7.  Semaphorins and plexins as therapeutic targets.

Authors:  Thomas Worzfeld; Stefan Offermanns
Journal:  Nat Rev Drug Discov       Date:  2014-08       Impact factor: 84.694

8.  ZEB-1, a repressor of the semaphorin 3F tumor suppressor gene in lung cancer cells.

Authors:  Jonathan Clarhaut; Robert M Gemmill; Vincent A Potiron; Slimane Ait-Si-Ali; Jean Imbert; Harry A Drabkin; Joëlle Roche
Journal:  Neoplasia       Date:  2009-02       Impact factor: 5.715

9.  Successful inhibition of tumor development by specific class-3 semaphorins is associated with expression of appropriate semaphorin receptors by tumor cells.

Authors:  Boaz Kigel; Asya Varshavsky; Ofra Kessler; Gera Neufeld
Journal:  PLoS One       Date:  2008-09-26       Impact factor: 3.240

10.  Expression of Semaphorin 3F and Its Receptors in Epithelial Ovarian Cancer, Fallopian Tubes, and Secondary Müllerian Tissues.

Authors:  Christina D Drenberg; Sandra Livingston; Ren Chen; Patricia A Kruk; Santo V Nicosia
Journal:  Obstet Gynecol Int       Date:  2009-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.